| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Bunnage Mark E. | EVP, Chief Scientific Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON | /s/ Christiana Stevenson, Attorney-in-Fact | 18 Feb 2026 | 0002100735 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Common Stock | Tax liability | $1,113,556 | -2,283 | -18% | $487.76 | 10,631 | 13 Feb 2026 | Direct |